Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds
The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.
You may also be interested in...
Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.